CbdMD Company Insiders
| YCBD Stock | USD 0.85 0.01 1.19% |
CbdMD employs about 42 people. The company is managed by 14 executives with a total tenure of roughly 98 years, averaging almost 7.0 years of service per executive, having 3.0 employees per reported executive. Evaluation of CbdMD's management performance can provide insight into the firm performance.
CbdMD Management Team Effectiveness
The company has return on total asset (ROA) of (0.0944) % which means that it has lost $0.0944 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3313) %, meaning that it created substantial loss on money invested by shareholders. CbdMD's management efficiency ratios could be used to measure how well CbdMD manages its routine affairs as well as how well it operates its assets and liabilities. As of January 26, 2026, Return On Tangible Assets is expected to decline to -0.45. The current year's Return On Capital Employed is expected to grow to -1.77. At present, CbdMD's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 16.4 M, whereas Non Current Assets Total are forecasted to decline to about 4.2 M.The current year's Common Stock Shares Outstanding is expected to grow to about 4.9 M, whereas Net Loss is projected to grow to (63.3 M). cbdMD Inc shows 16.0 percent of its outstanding shares held by insiders and 5.63 percent owned by other corporate entities.
Shares in Circulation | First Issued 2016-06-30 | Previous Quarter 5.8 M | Current Value 8.9 M | Avarage Shares Outstanding 1.8 M | Quarterly Volatility 2.1 M |
CbdMD Workforce Comparison
cbdMD Inc is rated first in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 219,255. CbdMD adds roughly 42.0 in number of employees claiming only tiny portion of equities under Health Care industry.
CbdMD Profit Margins
The company has Profit Margin (PM) of (0.08) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.2) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.2.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.48 | 0.55 |
|
|
CbdMD Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CbdMD insiders, such as employees or executives, is commonly permitted as long as it does not rely on CbdMD's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, CbdMD insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Raines William F Iii over a month ago Acquisition by Raines William F Iii of 4000 shares of CbdMD subject to Rule 16b-3 | ||
Crosnoe Clark R. over two months ago Insider Trading | ||
Stephen Scott G. over two months ago Acquisition by Stephen Scott G. of 4000 shares of CbdMD subject to Rule 16b-3 | ||
Porter Jeffrey H over six months ago Acquisition by Porter Jeffrey H of 1572 shares of CbdMD subject to Rule 16b-3 | ||
Sellers Bakari T. over six months ago Acquisition by Sellers Bakari T. of 5000 shares of CbdMD subject to Rule 16b-3 | ||
Ghiloni Peter J. over six months ago Acquisition by Ghiloni Peter J. of 5000 shares of CbdMD subject to Rule 16b-3 | ||
Kennedy Thomas Ronan over six months ago Disposition of 5000 shares by Kennedy Thomas Ronan of CbdMD at 2.1 subject to Rule 16b-3 | ||
Roe Kevin Charles over six months ago Disposition of 14500 shares by Roe Kevin Charles of CbdMD subject to Rule 16b-3 |
CbdMD Notable Stakeholders
A CbdMD stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as CbdMD often face trade-offs trying to please all of them. CbdMD's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting CbdMD's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Ronan Kennedy | Principal CEO | Profile | |
| Robert Pettway | Director Relations | Profile | |
| Sybil Swift | VP CSO | Profile | |
| Zeb Booker | Chief Officer | Profile | |
| Raymond Coffman | CoFounder Chairman | Profile | |
| Kevin MacDermott | President | Profile | |
| John Weston | Director Relations | Profile | |
| Shannon Charles | Chief Officer | Profile | |
| Francisco Mangual | Senior Sales | Profile | |
| Bradley Whitford | Treasurer Officer | Profile | |
| Matthew Coapman | Chief Officer | Profile | |
| Lance Blundell | General Counsel | Profile | |
| David Johnson | Senior Development | Profile | |
| Sibyl Swift | VP Affairs | Profile |
About CbdMD Management Performance
The success or failure of an entity such as cbdMD Inc often depends on how effective the management is. CbdMD management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CbdMD management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CbdMD management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.43) | (0.45) | |
| Return On Capital Employed | (1.87) | (1.77) | |
| Return On Assets | (0.31) | (0.33) | |
| Return On Equity | (0.54) | (0.57) |
Please note, the presentation of CbdMD's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, CbdMD's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of CbdMD's management manipulating its earnings.
CbdMD Workforce Analysis
Traditionally, organizations such as CbdMD use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare CbdMD within its industry.CbdMD Manpower Efficiency
Return on CbdMD Manpower
| Revenue Per Employee | 456.9K | |
| Revenue Per Executive | 1.4M | |
| Net Loss Per Employee | 48.6M | |
| Net Loss Per Executive | 145.8M | |
| Working Capital Per Employee | 79.9K | |
| Working Capital Per Executive | 239.8K |
Complementary Tools for CbdMD Stock analysis
When running CbdMD's price analysis, check to measure CbdMD's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CbdMD is operating at the current time. Most of CbdMD's value examination focuses on studying past and present price action to predict the probability of CbdMD's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CbdMD's price. Additionally, you may evaluate how the addition of CbdMD to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Stocks Directory Find actively traded stocks across global markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |